KEYMED BIO-B News

Conoa-B (02162.HK): CM310 SAR phase III clinically successful product is expected to be approved within the year

中金公司Apr 29 16:41

Conoa-B (02162.HK): CM310 will soon be commercialized with differentiated pipeline layout in the early stages

廣發證券Apr 29 00:00

Conoa-B (2162.HK): Exclusive opportunity to reach the end of phase III allergic rhinitis

華泰證券Apr 28 00:00

Conoa-B (2162.HK): The pipeline is progressing smoothly and is about to enter a new commercialization cycle

長江證券Apr 15 14:26

Conoa-B (2162.HK): CM310 is expected to be approved by the end of the year and multiple pipelines will continue to advance

國泰君安Apr 3 14:16

Conoa-B (02162.HK): Commercialization of Sproximab is imminent, optimistic about domestic sales potential

國信證券Apr 1 18:51

Conoa-B (2162.HK): Immediate launch of self-exempt products, R&D and innovation are progressing steadily

中信建投證券Mar 30 00:00

Conoa-B (2162.HK): Forge ahead and take the lead

華泰證券Mar 28 16:16

Conoa-B (02162.HK): CM310 is expected to be approved for listing within the year, focusing on commercialization

中金公司Mar 28 08:06

Connoya (2162.HK): Spugibimab submits NDA for commercialization

西南證券Mar 27 19:51

Connor (2162.HK): Net loss in 2023 was slightly higher than expected; CM310's first-year sales guide was 500 million yuan

浦銀國際Mar 27 00:00

Conoa-B (2162.HK): Deeply involved in the double circuit of immune cancer, large single product IL-4R monoclonal antibody declared NDA

開源證券Feb 19 00:00

Connoah (2162.HK): CM310 is a leader in the field of imminent listing and self-exemption

西南證券Nov 30, 2023 00:00

Connoah-B (02162.HK): CMG901 post-line gastric cancer data can be expected to actively go overseas

華創證券Nov 29, 2023 19:46

Connoah-B (2162.HK): CMG901 potential verification pending clinical registration

華泰證券Nov 10, 2023 07:32

Connoah-B (02162.HK): CMG9011 clinical data release is expected to be the first to enter registered clinical trials

國信證券Nov 8, 2023 20:36

Connoah Biotech (2162.HK): CMG901 Backline Gastric Cancer ORR 42% Top 3 in Global R&D Progress

海通國際Nov 8, 2023 00:00

Connoah-B (2162.HK): Phase III data verifies BIC potential

華泰證券Oct 12, 2023 11:42

Connoah-B (2162.HK): Tumor-free two-wheel drive core assets are about to be put into production

財通證券Sep 9, 2023 00:00

B (02162.HK) 2023 Interim Report Review: Multiple R&D pipelines advance in an orderly manner, CM310 is expected to submit an NDA within the year

中信證券Aug 29, 2023 13:12